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In cells undergoing apoptosis, mitochondrial
outer-membrane permeabilization (MOMP) is
followed by caspase activation promoted by re-
leased cytochrome c. Although caspasesmedi-
ate the apoptotic phenotype, caspase inhibition
is generally not sufficient for survival following
MOMP; instead cells undergo a ‘‘caspase-inde-
pendent cell death’’ (CICD). Thus, MOMP may
represent a point of commitment to cell death.
Here,we identify glyceraldehyde-3-phosphatede-
hydrogenase (GAPDH) as a critical regulator of
CICD. GAPDH-expressing cells preserved their
clonogenic potential following MOMP, provided
that caspase activation was blocked. GAPDH-
mediated protection of cells from CICD involved
an elevation in glycolysis and a nuclear function
that correlated with and was replaced by an in-
crease in Atg12 expression. Consistent with
this, protection from CICD reflected an increase
in and a dependence upon autophagy, associ-
ated with a transient decrease in mitochondrial
mass. Therefore, GAPDH mediates an elevation
in glycolysis and enhanced autophagy that
cooperate to protect cells from CICD.
INTRODUCTION
Caspases orchestrate the apoptotic phenotype, including
DNA fragmentation, nuclear condensation, phosphatidylserine externalization, plasma membrane blebbing, and
other events (Fischer et al., 2003), but they are not neces-
sarily required for cell death under proapoptotic condi-
tions (Chipuk and Green, 2005). When the mitochondrial
pathway of apoptosis is engaged and cytochrome c is
released following mitochondrial outer-membrane perme-
abilization (MOMP), addition of caspase inhibitors fails to
rescue proliferating cells from death (Amarante-Mendes
et al., 1998; McCarthy et al., 1997; Xiang et al., 1996). Sim-
ilarly, cells from animals lacking Apaf-1 or caspase-9, in
which caspases fail to activate following MOMP, never-
theless undergo cell death that can be inhibited by Bcl-2
(Haraguchi et al., 2000). This ‘‘caspase-independent cell
death’’ (CICD) may occur as a consequence of mitochon-
drial failure and/or mediators released from the mitochon-
dria following MOMP (Green and Kroemer, 2004). Exam-
ples of potential mediators released from mitochondria
include apoptosis-inducing factor (AIF), endonuclease G,
Omi/HtrA2, and others. While each of these have been
shown to trigger cell death upon transient overexpression,
none have been shown to be essential for CICD, and their
roles remain controversial. An alternative possibility is that
cells die following MOMP due to eventual collapse of mi-
tochondrial function (Chipuk and Green, 2005).
An exception to this scenario may be found in sympa-
thetic neurons deprived of neurotrophic factors. These
cells release cytochrome c but can remain viable and re-
generate mitochondria upon readdition of growth factors,
provided that caspase activation is blocked (Martinou
et al., 1999; Deshmukh et al., 2000). This requires that
the mitochondria sustain function as indicated by trans-
membrane potential (DJm) (Deshmukh et al., 2000).
Persistence of DJm despite MOMP can be observed in
many cell types, provided that caspases are blockedCell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc. 983
Figure 1. GAPDH Protects Cells from Caspase-Independent Cell Death but Not from Apoptosis
(A) HeLa cells transduced with a virus encoding GAPDH were treated as indicated in the presence or in the absence of qVD-oph. Percent of viability
was measured by propidium iodide staining and flow cytometry analysis.984 Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc.
(Waterhouse et al., 2001). It therefore remains puzzling
why recovery from MOMP is not a common occurrence
when caspase activation is disrupted.
Recovery from MOMP would have important implica-
tions for oncogenesis, since regulation of caspase activa-
tion downstream of MOMP can therefore influence cell
survival. Tumor lines often lack APAF-1 (Liu et al., 2002;
Soengas et al., 2001; Wolf et al., 2001) or caspases
(Devarajan et al., 2002), and inhibitor of apoptosis proteins
(IAPs) that block activation of caspases are frequently
elevated in cancer (Ferreira et al., 2001; Krajewska et al.,
2003; Tamm et al., 2000). In one study a dominant-nega-
tive form of caspase-9 enhanced survival and proliferation
of transformed cells (Schmitt et al., 2002) and therefore it
remains possible that cells can undergo MOMP, recover,
and proliferate if caspase activation is inhibited.
In this study, we investigated the problem of survival
and proliferation following MOMP by searching for pro-
teins that specifically protect cells from CICD but not
apoptosis.
RESULTS
To understand the conditions under which proliferating
cells might recover from MOMP when caspase activation
fails to occur, we took advantage of an unbiased approach
using a functional screen for proteins that could sustain
clonogenic survival in cells induced to undergo apoptosis,
but only in the presence of caspase inhibitors (Figure S1 in
the Supplemental Data available online). We introduced
a retroviral cDNA library into Jurkat cells that were tran-
siently treated with a lethal concentration of staurosporine
(1 mM, 6 hr) and then maintained in the presence of a
pancaspase inhibitor, valine-aspartate-fluoromethylketone
(VD-fmk) (Yang et al., 2003). Control cultures of uninfected
cells treated in this manner consistently failed to contain
surviving cells (data not shown, see Amarante-Mendes
et al., 1998). Clones of infected cells that survived this
treatment were retested by again inducing apoptosis,
plus or minus caspase inhibitor, and those that prolifer-
ated only in the presence of the inhibitor were further eval-
uated. The retroviral inserts in such clones were recovered
by PCR and characterized. In this way, we identified
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
a potential inhibitor of ‘‘caspase -independent’’ but not
caspase-dependent cell death.
We evaluated the effects of GAPDH in HeLa cells
subjected to proapoptotic conditions in the presence orabsence of the pancaspase inhibitor quinolyl-valyl-O-
methylaspartyl-[2,6-difluorophenoxy]-methyl ketone (qVD-
oph) (Figure 1). Under these conditions, cells rapidly
underwent caspase-dependent cell death, and in the
presence of a caspase inhibitor a majority of cells sus-
tained membrane integrity for 72 hr or more (Figure 1A).
GAPDH protein levels (Figure 1B) and enzymatic activity
(Figure 1C) declined in the parental line upon transient
treatment with a proapoptotic agent and culture with cas-
pase inhibitor, prior to any substantial death in the cells. In
contrast, enforced expression of GAPDH sustained ex-
pression and enzymatic activity at approximately normal
levels. HeLa cells with or without GAPDH died upon tran-
sient treatment with staurosporine (STS), etoposide
(Etop.), or actinomycin D (Act D), and addition of qVD-
oph failed to protect HeLa cells from these treatments,
as measured by clonogenic survival (Figures 1D and 1E).
However, HeLa cells ectopically expressing GAPDH
showed clonogenic growth following these treatments,
provided the caspase inhibitor was present (Figures 1D
and 1E). This effect was also observed in HeLa expressing
GAPDH in the presence of the pancaspase inhibitor VD-
fmk (Figure S2). The survival and proliferation of HeLa cells
expressing GAPDH exposed to proapoptotic agents in the
presence of caspase inhibitors was also observed as cell
accumulation (Figure 1F) and by dilution of carboxy-fluo-
rescein diacetate, succinimidyl ester (CFSE) (Figure S3).
At substantially higher concentrations of the cytotoxic
agents tested, no protection was afforded by expression
of GAPDH plus caspase inhibitors (data not shown).
Oncogenes such as Myc and E1A induce cell prolifera-
tion and apoptosis, such that transformation is not seen
unless the apoptotic pathway is blocked or evaded
(Evan et al., 1992; Green and Evan, 2002). Tumor suppres-
sion by apoptosis proceeds predominantly via the mito-
chondrial pathway accounting for the cotransforming
activity of Bcl-2, which blocks this pathway (Green and
Kroemer, 2004). However, despite the fact that tumors fre-
quently repress APAF-1 expression (Ferraro et al., 2003),
recent studies have failed to find an effect of APAF-1
deficiency on transformation by such oncogenes in
lymphocytes or early passage MEF (Scott et al., 2004).
However, if enforced expression of GAPDH can allow re-
covery of cells following MOMP (provided caspases are
not engaged), then APAF-1 deficiency might allow trans-
formation to occur. Therefore, early passage MEF (less
than or equal to passage 5) from wild-type or APAF-1 null
mice, were transduced with E1A plus or minus GAPDH.(B) HeLa cells transduced with a control retrovirus or with a virus encoding GAPDH were treated with 1 mM staurosporine (STS) in the presence of
20 mM qVD-oph. After the indicated times GAPDH expression was assessed by Western blot.
(C) Same as in (B) in the presence or absence of qVD-oph. *p < 0.01 versus vector with qVD-oph.
(D) HeLa cells (transduced with control or GAPDH encoding retrovirus) were treated for 6 hr with Act D, etoposide, or STS as indicated ± the caspase
inhibitor qVD-oph (20 mM). The caspase inhibitor was added 30 min before the apoptotic agents and replaced periodically at 24 hr intervals for 3 days.
Colonies were stained with methylene blue and assessed 12 days after treatment.
(E) Treatment as in (D). Quantitation of the number of colonies under each condition 12 days after treatment.
(F) Cells (13 104/well) were treated for 6 hr as indicated in the presence of qVD-oph (20 mM). Viable cells were counted by trypan blue exclusion at the
indicated times (up to 12 days). All results in the figure represent mean ± SD of three to five independent experiments.Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc. 985
Figure 2. GAPDH Protects Cells from
CICD
(A) Early passage MEFs (less than or equal to
passage 5) from wild-type or Apaf-1 null mice
were transduced with E1A plus a control retro-
virus or with GAPDH. After 2 weeks of selec-
tion, colonies were visualized by methylene
blue staining.
(B) Cells were treated as in (A) with the indi-
cated combination of retroviruses expressing
E1A, Ras, and/or GAPDH.
(C) Jurkat cells were maintained in low (0.3 mM)
or high (4 mM) glucose for 2 weeks, and then
activated by culture on anti-CD3 for 24 hr.
GAPDH expression was determined by immu-
noblot (right). The cells were then treated with
Act D (0.5 mM, 6 hr, ± qVD-oph) and plated at
approx. 1 cell per well in low or high glucose.
Wells with proliferating cells were assessed
by visual inspection after 8 days.
In (B) and (C), results are mean ± SD from three
independent experiments.Wild-type MEF did not survive expression of E1A, whether
or not GAPDH was expressed, and similarly, APAF-1-
deficient MEF did not proliferate if transduced with E1A
in the absence of GAPDH (Figure 2A). However, APAF-1
null MEF survived and proliferated following expression
of E1A plus GAPDH (Figure 2A). In a similar experiment,
cells were transduced with E1A alone or E1A plus Ras, ±
GAPDH (Figure 2B). Ras is capable of providing anti-
apoptotic signaling via AKT (Bonni et al., 1999), upstream
of MOMP (Kennedy et al., 1997). While both wt and
APAF-1 null MEF failed to survive expression of E1A alone,
both MEF generated equivalent numbers of colonies with
E1A plus Ras. Expression of GAPDH permitted colony
formation in APAF-1 null MEF expressing E1A to the986 Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc.same extent seen with E1A plus Ras, but did not protect
wt MEF.
To ensure that the surviving clones did not arise be-
cause of mutations in p53, three clones from the E1A
plus GAPDH transduced group in the experiment shown
in Figure 2B were expanded and the p53 status assessed
by sequencing. No mutations were detected (data not
shown). In addition, APAF-1 null cells expressing E1A
plus GAPDH showed robust expression of the p53-
responsive gene p21WAF1 in response to DNA damage
(Figure S4), indicating that p53 is functional in these cells.
Activation of T lymphocytes elevates GAPDH levels
(Teague, et al., 1999), and therefore we asked if such ac-
tivation can promote protection from CICD. We treated
Jurkat T cells with anti-CD3 to activate them, and ob-
served that GAPDH expression increased (Figure 2C,
right). We then treated the cells with Act D (0.5 mM, 6 hr, ±
qVD-oph) prior to plating them at approx. 1 cell per
well (±qVD-oph), and assessed cell survival and prolifera-
tion after 8 days. We observed that while no cells survived
in the absence of the caspase inhibitor, a small proportion
of activated Jurkat cells survived in the presence of the in-
hibitor, suggesting that activation had protected the cells
from CICD (but not apoptosis). Interestingly, this protec-
tion was not seen in Jurkat cells that were maintained in
low glucose, a condition under which GAPDH does not
protect HeLa cells from CICD (see below and Figures 4A
and 4B). These results suggest that physiological eleva-
tion of GAPDH can protect activated T lymphocytes
from CICD. This may explain the intriguing finding that T
cells with a memory phenotype accumulate in mice carry-
ing a cytochrome c mutation that disrupts the ability of the
protein to induce caspase activation following MOMP
(Hao, et al., 2005).
Clearly, one way by which GAPDH might protect against
cell death would be to inhibit MOMP and cytochrome c re-
lease in a manner analogous to Bcl-2 (Kluck et al., 1997;
Kuwana and Newmeyer, 2003). We introduced cyto-
chrome c-GFP into HeLa cells expressing GAPDH (Gold-
stein et al., 2000) and observed that cytochrome c release
occurred in a majority of cells induced to undergo apopto-
sis in the presence of caspase inhibitors, whether or not
the cells expressed GAPDH (Figure 3A). Strikingly, while
no recovery of mitochondrial cytochrome c was observed
in the control cells, such recovery was eventually ob-
served in cells expressing GAPDH (data not shown).
This, however, did not resolve the issue of whether or
not those cells that had released cytochrome c were
able to restore their mitochondria and proliferate.
Therefore, we plated HeLa cells expressing cytochrome
c-GFP (±GAPDH) at approximately one cell per well in mi-
crowell cultures. Following overnight culture, cells were
treated with Act D (for six hrs or overnight) in the presence
of qVD-oph, washed, and the caspase inhibitor was again
added. Wells were scored for cells containing mitochond-
rially-localized cytochrome c-GFP (see Table S1 for
examples). Strikingly, we consistently observed wells
that contained only cells showing cytochrome c release
subsequently harboring cells displaying relocalization of
cytochrome c-GFP to the mitochondria and evidence of
cell proliferation. Examples are shown in Figures 3B and
S5A. This recovery and proliferation was never observed
in the absence of caspase inhibitors or in cells without
enforced expression of GAPDH (data not shown). The mi-
tochondrial localization of the cytochrome c-GFP was
confirmed by costaining with TMRE (Figure S5B).
During apoptosis, a caspase-dependent loss of DJm
quickly follows release of cytochrome c, and this loss is
substantially delayed if caspase activation is blocked
(Ricci et al., 2004; Waterhouse et al., 2001). Therefore,
we assessed DJm using the potentiometric dye TMRE
in HeLa cells treated with cytotoxic agents with or withoutcaspase inhibitors. GAPDH expression had no effect on
the maintenance of DJm during caspase-dependent ap-
optosis (Figure 3C) while the addition of caspase inhibitor
delayed loss of DJm in control HeLa cells, this subse-
quently declined as previously described (Waterhouse
et al., 2001). Enforced expression of GAPDH extended
the maintenance of DJm in the presence of caspase in-
hibitors (Figures 3C and S6). To determine if this effect
contributed to protection from CICD, cells were treated
to induce MOMP in the presence of caspase inhibitor,
and three days later sorted into populations with low
(M1) or high (M2) DJm (Figure 3D). While no clonogenic
growth was observed in either population of vector control
cells, GAPDH-expressing cells with high DJm showed
a dramatic enhancement of clonogenic survival (seen as
a ‘‘lawn’’ of growing cells) as compared to those cells
with low DJm (seen as individual colonies). Therefore,
maintenance of DJm by GAPDH correlates with protec-
tion from CICD.
GAPDH is a multifunctional enzyme with a role in glycol-
ysis and other less well understood roles in membrane fu-
sion, transcriptional coactivation, and DNA repair (Naka-
gawa et al., 2003; Glaser et al., 2002; Kaneda et al.,
1997; Zheng et al., 2003). We reasoned that a GAPDH-
mediated elevation in glycolytic metabolism and a conse-
quent maintenance of ATP generation might provide the
requisite energy for mitochondrial regeneration following
MOMP in the absence of caspase activation. Indeed, we
found that cells with enforced GAPDH expression showed
elevated ATP levels when maintained in high glucose
(10 mM) but not low glucose (0.1 mM) (Figures 4A and S7).
This elevation in ATP was likely due to glycolysis, since
the complex V inhibitor oligomycin did not inhibit it, but
did suppress ATP levels in cells maintained in low glucose.
The increase in ATP appeared to have a role in protection
from CICD, since such protection was seen only when
cells were maintained in high glucose (Figure 4B). Un-
treated cells maintained in high or low glucose were
equally viable, and no survival was observed in those cells
treated to undergo apoptosis in the absence of caspase
inhibitors (data not shown).
CICD has been suggested to occur through the gener-
ation of reactive oxygen species (ROS) (Chipuk and
Green, 2005). However, we did not observe any effect of
enforced GAPDH expression on ROS levels in cells under-
going CICD (Figure 4C). Three different ROS scavengers
effectively reduced hydrogen peroxide levels in these cells
(Figure 4C), but none protected cells from CICD nor en-
hanced the protection seen with GAPDH (Figure 4D). We
were therefore unable to demonstrate a role for ROS scav-
enging in protection from CICD under the conditions used
in this study.
In addition to its glycolytic function, and consistent with
its C-terminal dependent nuclear localization (Brown et al.,
2004; Mazzola and Sirover, 2003), GAPDH is also involved
in several nuclear functions (Zheng et al., 2003; Sundararaj
et al., 2004; Meyer-Siegler et al., 1991) and translocates to
the nucleus upon cellular stress (Saunders et al., 1999;Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc. 987
Figure 3. Cytochrome c-GFP Release and Persistence of DJm during Caspase-Independent Cell Death
(A) Control or GAPDH-expressing HeLa cells were transduced with a cytochrome c-GFP encoding vector. Mitochondrial retention of cytochrome
c-GFP was examined by flow cytometry (see Supplemental Experimental Procedures) in cells treated for 6 hr with Act D (0.5 mM) ± qVD-oph
(20 mM). Results represent mean ± SD of four independent experiments.
(B) GAPDH-expressing HeLa cells transduced with the cytochrome c-GFP encoding vector were individually seeded in microwells on glass bottom
dishes and treated with Act D (0.2 mM) plus qVD-oph (20 mM) for 6 hr. Mitochondrial localization of cytochrome c-GFP was analyzed by confocal
microscopy 3 and 10 days after stimulation.
(C) Cells were treated as in A and loss of DJm during caspase independent cell death was measured by flow cytometry using the fluorescent dye
TMRE. Results represent mean ± SD of three independent experiments.
(D) 3 days after treatment with STS (0.5 mM) plus qVD-oph (20 mM), cells were stained using TMRE (filled curve in the FACS profile) and FACS sorted for
high (M2) or low (M1) DJm. Cells were then seeded at 1 3 104 cells/dish and assessed 7 days later. In the FACS profiles, black lines represent
untreated cells and dotted lines represent cells treated with the uncoupling agent FCCP (10 mM), both populations were stained with TMRE (50 nM).988 Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc.
Figure 4. Increased ATP Production Induced by GAPDH but Not ROS Scavenging Is Associated with Its Protective Effect
(A) Control or GAPDH-expressing HeLa cells were cultured for a minimum of 2 weeks in glucose-free DMEM, supplemented with D-glucose (10 mM or
0.1 mM), sodium pyruvate (5 mM), uridine (5 mM), and 10% dyalized FBS. ATP was measured after 2 hr incubation with or without oligomycin (10 mM).
Results are mean ± SD of three experiments. *p < 0.05 versus vector values, **p < 0.05 versus GAPDH values.
(B) Cells growing in the presence of high or low glucose and treated for 6 hr with Act D (0.5 mM), etoposide (5 mM), or STS (1 mM) ± qVD-oph (20 mM).
Colonies were stained with methylene blue and assessed 12 days after treatment.
(C) Control or GAPDH-expressing HeLa cells were preincubated for 1 hr with MitoQ (1 mM), BHA (200 mM) or NAC (10 mM) and then treated with Act D
(0.5 mM) or STS (1 mM) in the presence of qVD-oph (20 mM) for 6 hr. Data shown are mean of fluorescence intensity (M.F.I.) ± SD from spectro-
fluorimetric analyses of H2DCFDA-stained cells. *p < 0.05 versus vector without antioxidant pretreatment values, **p < 0.05 versus GAPDH without
antioxidant pretreatment values.
(D) Cells were treated as in C ± qVD-oph (20 mM). Colonies were stained with methylene blue and assessed 12 days after treatment.Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc. 989
Figure 5. Effects of GAPDH Mutants
(A) Schematic representation of different GAPDH mutants, used in this study. GAPDHD2 lacks the putative nuclear localization sequence (NLS) of GAPDH.
(B) ATP levels in HeLa cells stably expressing each construct represented in A or with a combination, as indicated. *p < 0.05 versus vector values.
(C) GAPDH activity of HeLa cells stably expressing the constructs represented in A was measured as described in the Experimental Procedures. In (B)
and (C), results represent mean ± SD from three independent determinations. *p < 0.05 versus vector values.
(D) HeLa cells expressing the mutants shown in A were treated for 6 hr with Act D (0.5 mM) ± qVD-oph (20 mM). Colonies were stained with methylene
blue and assessed 12 days after treatment.
(E) HeLa cells expressing the WT, GAPDH149S/176F, GAPDHD2 or a combination of both mutant forms of GAPDH were exposed to Act D (0.5 mM) +
qVD-oph (20 mM). Stable double-expressing cell lines were generated by transducing each mutant in the order indicated. Colonies were stained with
methylene blue and assessed 12 days after treatment.Dastoor and Dreyer, 2001). We generated mutants of
GAPDH (Figure 5A) and examined their abilities to elevate
ATP and localize to the nucleus. The V5-tagged mutants990 Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc.were stably introduced into HeLa cells and their expres-
sion levels verified to be equivalent via immunoblot (data
not shown). Of these, only one (GAPDHD2) elevated ATP
levels and GAPDH enzymatic activity to the same extent
as that seen with wild-type GAPDH (Figures 5B and 5C).
Another mutant (GAPDH149S/176F) while failing to elevate
ATP levels, localized to the nucleus upon cellular stress,
as observed with wild-type GAPDH (Figure S8).
We then tested these mutants for their ability to rescue
cells following MOMP in the absence of caspase activa-
tion. None of the mutants when expressed in HeLa cells
were able to promote survival following treatment with
cytotoxic agents in the presence of caspase inhibitors
(Figure 5D) and neither were they capable of sustaining
clonogenic survival in APAF-1 null MEF transduced with
E1A (Figure S9). However, in both cases wild-type GAPDH
was effective. We therefore cotransfected the ATP-elevat-
ing GAPDHD2 mutant and the GAPDH149S/176F mutant ca-
pable of nuclear localization. In contrast to each mutant
alone, both together reproduced the effect of wild-type
GAPDH such that the cells expressing both GAPDHD2
and GAPDH149S/176F recovered from cytotoxic treatment
in the presence of caspase inhibitors (Figure 5E). In this
experiment, stable HeLa lines expressing GAPDHD2 or
GAPDH149S/176F were each stably transduced with the
other GAPDH mutant to generate stable double-express-
ing lines (Figure S10A). Similar results were obtained fol-
lowing treatment with etoposide or staurosporine plus
caspase inhibitor (Figure S10B). No cell survival was ob-
served in cells treated with the apoptosis-inducing agents
in the absence of caspase inhibitor (data not shown). Sim-
ilarly, cointroduction of both mutants with E1A permitted
transformation of APAF-1 deficient (but not wild-type)
MEF, albeit with less efficiency than seen with wt GAPDH
(Figure S11). Thus, both the glycolytic function and nu-
clear effects of GAPDH appear to be required for recovery
from MOMP in the absence of caspase activation.
Autophagy is a process of cellular survival that is often
associated with forms of cell death that are caspase-inde-
pendent (Levine and Yuan, 2005). However, the role of au-
tophagy in dying cells remains controversial. Examination
of cells treated with Act D or plus qVD-oph showed in-
creased numbers of autophagic vesicles in GAPDH-
expressing versus vector-control cells (Figures 6A–6C).
Similar observations were made in cells expressing LC3-
GFP, in which punctate distribution of the fluorescent pro-
tein correlates with engagement of autophagy (Kabeya,
et al., 2000) (Figure S12). These data indicated that
GAPDH-mediated protection against CICD might involve
the engagement of autophagy. To determine if this may
be the case, GAPDH-expressing cells, ± caspase inhibitor
were preincubated for 6 hr with the autophagy inhibitors 3-
methyladenosine (3-MA) or Bafilomycin A1 (BafA1) fol-
lowed by a 6 hr treatment with STS. While neither 3-MA
nor BafA1 inhibited growth in cells not treated with STS,
protection from CICD was inhibited (Figure S13). To ad-
dress the role of autophagy more rigorously, we employed
shRNA to stably knock down Atg5, a critical component of
the autophagic pathway (Figure S14); these stable lines
grew with nearly identical kinetics to control cells in terms
of doubling time and clonogenicity (data not shown). How-ever, GAPDH expression failed to protect cells from CICD
when inhibition of autophagy was achieved by stable
knockdown of Atg5 (Figure 6D).
Autophagy can function in the removal of damaged
mitochondria, a process called ‘‘mitophagy’’ (Kundu and
Thompson, 2005). It has previously been noted that mi-
tophagy occurs in neurons and HeLa cells that have
been treated with cytotoxic agents in the presence of cas-
pase inhibitors, and this is blocked by Bcl-2 (Xue et al.,
2001), suggesting that it may be a consequence of
MOMP. Further, it has been suggested that mitochondria
that have undergone a permeability transition (mPT) are
removed by such mitophagy (Elmore et al., 2001). Al-
though we have not found evidence of an mPT during
MOMP (Waterhouse et al., 2001; Ricci et al., 2003,
2004), we examined the possibility that GAPDH-enhanced
autophagy may promote removal of mitochondria in cells
protected from CICD. We found that a subpopulation of
cells displayed a reduced mitochondrial mass following
MOMP in the presence of caspase inhibitors, and this
was exacerbated by enforced expression of GAPDH (Fig-
ures 6E and 6F). This effect of GAPDH was not observed
with the GAPDHD2 mutant (Figure S15) and was blocked
by inhibition of autophagy by stable knockdown of Atg5
(Figures 6E and 6F). Thus, one way in which GAPDH
may protect cells following MOMP is through autophagic
removal of damaged mitochondria. Indeed, in cells ex-
pressing GAPDH and subjected to conditions for induc-
tion of CICD, colocalization of some (but not all) mitochon-
dria with LC3-GFP was observed (Figures 6G and S16).
We suspect that this is a dynamic process that may re-
move damaged mitochondria over an extended time pe-
riod, as suggested by others (Elmore, et al., 2001; Xue,
et al., 2001).
Nuclear GAPDH has been implicated in transcriptional
regulation (Zheng et al., 2003). We therefore examined
differential gene expression by RNG/MRC microarray in
vector- or GAPDH-expressing cells treated with cytotoxic
agents (data not shown). Of particular note was the differ-
ential expression of Atg12 that was further examined by
real-time PCR (Figure 7A) and at the protein level (Figures
7B and 7C). We observed that Atg12 mRNA expression
was induced by a brief (6 hr) treatment with Act D to
a greater extent in those cells expressing GAPDH and
not the vector control cell line. It is useful to note that
upon transient (e.g., six hour) treatment with similar or
higher doses of Act D, transcriptional activity rapidly re-
covers in cells (Sawicki and Godman, 1972), and that
Act D-induced apoptosis is probably a consequence of
DNA damage (Hietanen, et al., 2000; Mischo, et al.,
2005). This expression resulted in sustained Atg12 protein
levels in the GAPDH-expressing cells (Figures 7B and 7C).
Interestingly, GAPDHD2 failed to have this effect on Atg12
expression (Figure 7C).
Atg12 participates in the process of autophagy, upon
conjugation to Atg5 (Levine and Yuan, 2005). To deter-
mine if GAPDH-induced Atg12 expression contributes to
protection from CICD, we asked if it could substitute forCell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc. 991
Figure 6. Autophagy Induced by GAPDH Protects Cells from Caspase-Independent Cell Death
(A) Representative electron microscopic image of GAPDH-expressing HeLa cells 4 days after Act D (0.5 mM) + qVD-oph (20 mM) exposure. Arrow-
heads denote autophagosomes. Scale bars represent 1 mm.
(B) Examples of autophagosomes. GAPDH-expressing HeLa cells treated cells as in (A). The double membrane characteristic of autophagy can
clearly been seen. Scale bar represents 6 mm.
(C) Electron microscopic quantitation of autophagy in vector and GAPDH-expressing HeLa cells treated for 6 hr with Act D (0.5 mM) ± qVD-oph
(20 mM). Results shown represent the mean ± S.D number of autophagosomes per cell, profiled for 18 cells per condition. *p < 0.000001 versus
vector values.
(D) Control or GAPDH-expressing HeLa cells, or cells stably expressing an shRNA for Atg5 (Atg5 kd), were treated for 6 hr with STS (1 mM) + qVD-oph
(20 mM). Colonies were stained with methylene blue and assessed 12 days after treatment.992 Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc.
nuclear GAPDH in cooperating with the glycolysis-
elevating GAPDHD2 mutant to sustain survival. HeLa
cells expressing Atg12 with or without GAPDHD2 were
subjected to treatment with STS and cultured with or
without caspase inhibitor. While Atg12 or GAPDHD2 did
not protect cells on its own, substantial protection
from CICD was observed in cells expressing both (Fig-
ure 7D). Two other components of the autophagy path-
way, LC3 and ATG5, failed to protect cells from CICD,
either alone or with GAPDHD2 (Figures S17A and S17B).
These data suggest the possibility that the nuclear func-
tion of GAPDH in protecting cells from CICD is mediated
by the transcriptional up-regulation of Atg12. Whether
this reflects a direct or indirect effect of GAPDH remains
to be determined.
DISCUSSION
During apoptosis, MOMP does not, by itself, cause a rapid
loss of mitochondrial function (Martinou et al., 1999,
Waterhouse et al., 2001, Ricci et al., 2003). However,
with time the absence of an intact outer membrane com-
promises these organelles and commits the cell to death
even under conditions in which caspase activation is dis-
rupted or prevented. During this process, GAPDH levels
decline. Such a loss of GAPDH has been described to
occur via a chaperone-mediated degradation mechanism
in nutrient-deprived cells (Majeski and Dice, 2004).
A cell lacking the downstream elements of the mito-
chondrial pathway (such as APAF-1) gains no growth ad-
vantage when provided with a proliferative signal (Scott
et al., 2004). However, if GAPDH levels are sufficiently
sustained, this disruption in caspase activation can permit
cellular recovery and could contribute to oncogenic trans-
formation. Tumors frequently have defects in APAF-1
expression (Ferraro et al., 2003) and elevated GAPDH
expression (Revillion et al., 2000; Rondinelli et al., 1997;
Schek et al., 1988; Tokunaga et al., 1987). Together, these
may have contributed to their survival from the initial trans-
forming event. Similarly, caspase activation downstream
of the mitochondria can be antagonized by inhibitor of
apoptosis proteins, such as XIAP (Deveraux et al., 1998),
which is often found to be elevated in transformed cells
(Ferreira et al., 2001; Krajewska et al., 2003; Tamm
et al., 2000).
How does GAPDH contribute to recovery from MOMP?
In part, this appears to be through maintenance of mito-
chondrial DJm, probably through elevation of ATP, whichcan sustainDJm via F0F1ATPase (complex V) activity. Be-
cause HeLa cells have elevated activity of the rate-limiting
glycolytic enzyme phosphofructokinase (PFK1) (Chesney
et al., 1999, Hue and Rider, 1987), increased levels of
GAPDH directly result in higher ATP levels. Maintenance
of DJm is required for most mitochondrial functions
including protein import, and therefore any repair or dy-
namic processes in this organelle.
In addition, other functions of GAPDH appear necessary
for full recovery from MOMP in the absence of caspase
activation. In particular, the enforced expression of
GAPDH enhances a process whereby mitochondria are
removed in a manner that depends on Atg5. It is likely
that this represents an autophagic removal of damaged
mitochondria, consistent with our observed association
of LC3 with mitochondria in GAPDH-expressing cells sub-
jected to conditions for CICD. In the nucleus, GAPDH can
participate in transcription, including regulation of the
expression of Histone 2B (Zheng et al., 2003), cell cycle
regulation (Carujo, et al., 2006), and DNA repair (Meyer-
Siegler et al., 1991), among other functions (reviewed in
Sirover 1999). Our studies indicate that nuclear GAPDH
promotes Atg12 expression under conditions that induce
MOMP, and that enforced expression of Atg12, but not
LC3 or Atg5, obviated the requirement for nuclear GAPDH
in protection from CICD. It remains to be seen whether this
effect is due to maintenance of autophagy. It should be
noted that our findings do not indicate that expression of
Atg12 induces autophagy per se, but that such expression
may limit autophagy occurring as a consequence of
MOMP under conditions for CICD. Why this should be
the case remains unclear.
While autophagy has also been proposed to promote
cell death under some conditions (Levine and Yuan,
2005), our results point to a survival role for this process
in cells subjected to conditions for CICD. If CICD is
a form of ‘‘autophagic cell death,’’ any accompanying au-
tophagy is likely to represent engagement of this protec-
tive process, which fails if levels of GAPDH fall below a req-
uisite threshold. It is tempting to speculate that autophagy
contributes to protection from CICD by promoting the
removal of terminally damaged mitochondria, while en-
hanced glycolysis and elevated ATP provide energy for
this process as well as other aspects of cellular repair
and survival. The approximate 7–10 day delay in restora-
tion of proliferative potential in those GAPDH-expressing
cells induced to undergo MOMP may therefore represent
the time required for repair and expansion of functional
mitochondria, until a critical cohort is attained.(E) GAPDH promotes a reduction in mitochondrial mass under conditions of CICD. Mitochondrial mass was assessed by staining with nonyl-acridine
orange 48 hr after treatment with Act D (6 hr) plus qVD-oph, and analyzed by FACS. Control or GAPDH-expressing HeLa with stable knockdown of
Atg5 (ATG5 III) were examined.
(F) As in (D), results from three independent experiments. Values are mean ± SD (G) LC3 localizes to mitochondria under conditions of CICD. HeLa
cells expressing GAPDH were transfected with constructs for expression of mitochondrially-localized DsRed and LC3-GFP, and treated with STS
(1 mM, 6 hr) plus qVD-oph. Localization of fluorescent proteins was assessed 48 hr later. Additional images are shown in Figure S16. Examples of
LC3-GFP and Mito-DsRed colocalization are indicated by white arrows.Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc. 993
Figure 7. Atg12 Increase in GAPDH-Expressing Cells after a Cell Death Stimulus Is Sufficient to Replace the Requirement for
Nuclear GAPDH for Protection from CICD
(A) HeLa cells (transduced with control or GAPDH encoding retrovirus) were exposed for 6 hr to Act D (0.2 mM) ± qVD-oph (20 mM). 24 hr after treat-
ment, total mRNA was isolated and assessed by real-time RT-PCR for Atg12 expression. Absolute mRNA values were determined, normalized to
cyclophilin A and reported as arbitrary units. Similar results were obtained with other housekeeping genes as controls (data not shown). Abbreviation:
NT, nontreated cells.
(B) Cells were treated as in (A), and level of expression of Atg12 and Beclin-1 in the stable lines were assessed by immunoblot at the indicated times.
The figure shows quantification of Atg12 protein levels versus the loading controls in three independent experiments.
(C) As in (B), and showing the effect of GAPDHD2.
(D) Cells expressing GAPDHD2 were transduced with a construct for expression of Atg12 and 24 hr later treated as in (A). Colonies were assessed
12 days after treatment.994 Cell 129, 983–997, June 1, 2007 ª2007 Elsevier Inc.
EXPERIMENTAL PROCEDURES
Retroviral Library and Screening
Retroviral libraries were generated using cDNA derived from MCF-7
cells (cells expressing a defective caspase-3) in the retrovirus vector
pMX (Onishi et al., 1996). The library was kindly provided by Dr. E. Rou-
salati (Burnham Inst., La Jolla, CA). The recombinant retrovirus library
was used to infect Jurkat cells as described below. 48 hr later, those
cells were subjected to selection (in the presence of staurosporine
0.5-1 mM ± 50 mM VD-fmk, the latter kindly supplied by Maxim Pharma-
ceuticals, San Diego, CA) and surviving clones were isolated by limiting
dilution. Only cells presenting a resistance to caspase-independent
death (i.e., resistance to staurosporine in the absence of VD-fmk)
were further characterized. The cDNAs expressed in those cells
were amplified by PCR using retroviral oligonucleotides and then
sequenced.
Virus Production and Infection
Plasmids containing the wt or the mutated forms of GAPDH together
with Hit 60 (MoMuLV gag-pol expression plasmid) and pCG (VSV-G
envelope protein expression vector) were transfected into 293T cells
using the standard Ca2+-phosphate procedure. After 36 hr, the virus-
containing medium was filtered (0.4 mm SFCA membrane filter;
Nalgene) and supplemented with 10 mg/ml polybrene (Sigma) (first
supernatant). Viruses were collected for an additional 10 hr as before
(second supernatant). Target cells were plated at 50% confluence
and incubated overnight. For infections, the culture medium was
replaced by the appropriate first supernatant, the plate centrifuged
for 10 min at 1500 rpm and then incubated at 37C for 10 hr. The infec-
tion process was repeated using the second supernatant. Forty-eight
hrs later, infected cell populations were purified using the appropriate
selection: 1 mg/ml of puromycin or 1 mg/ml of G418. After 1 week
expression of the tagged proteins was assessed by Western blot.
The same procedure was used for cytochrome c-GFP (cloned into
pBabe-Puro vector; Goldstein et al., 2000) expression in HeLa cells
stably expressing GAPDH.
Cell Culture and Induction of Cell Death
HeLa cells were grown in Dulbecco’s Modified Essential Medium
(DMEM, GIBCO BRL) and Jurkat cells (human acute T cell leukemia)
were cultured in RPMI-1640 (GIBCO BRL). All media were supple-
mented with 2 mM glutamine, antibiotics and 10% fetal bovine serum
(FBS). For experiments involving glucose limitation, cells were cultured
in glucose-free DMEM, and the required amount of D-glucose added
together with 2 mM glutamine, 5 mM uridine, 5 mM sodium pyruvate
and 10% dialyzed FBS.
To induce death, cells were treated with actinomycin D (0.2-0.5 mM),
staurosporine (0.5-1 mM), or etoposide (5-10 mM) for 6 hr then washed,
fed with fresh medium and cultured for indicated periods of time.
Caspase inhibition was achieved by including 20 mM of qVD-oph
(Qbiogene, Irvine, CA) or 50 mM VD-fmk (Yang et al., 2003) in the
medium where indicated. The caspase inhibitors were added 30 min
before the apoptotic stimuli and replaced periodically at 24 hr intervals.
RNA Interference
Complementary sense and antisense oligonucleotides corresponding
to nucleotides 89–107, 354–371, and 661–679 of human Atg5 were
annealed and cloned into pSuper generating pSuper Atg5 I, II and III
respectively. pSuper Atg5 II and Atg5 III were digested with EcoRI
and XhoI and the restriction fragments encoding the H1 promoter
and shRNA sequence were subcloned into pSuper RV puro via
EcoRI/XhoI restriction sites. Retrovirus production and infection of
GAPDH-V5 expressing Hela cells was done as described above. Sta-
bly transduced cells were selected and grown in puromycin (1ug/ml).
Atg5 mRNA expression was analyzed using the following oligonucleo-
tides: sense 50-TGGGATTGCAAAATGACAGA-30 and antisense 50-TTTC
CCCATCTTCAGGATCA-30.To assess knockdown of Atg5 protein, human Atg5 (MGC clone
number 110866) was amplified by PCR using the following oligonucle-
otides: sense 50-ACGCGTCGACCATGACAGATGACAAAGATGTGCT
TC-30 encoding a SalI restriction site and antisense 50-ATAGTT
TAGCGGCCGCTCAATCTGTTGGCTGTGGGATG-30 encoding a NotI
restriction site. The PCR product was cloned into PMT2-HA via SalI/
NotI restriction sites, and employed for transient expression. Expres-
sion was assessed by immunoblot for the tagged protein.
Statistics
Statistics were performed using a two tailed distribution Student’s
t test. All values shown in the text and figures are ±SD.
Additional methods are provided in the Supplemental Data.
Supplemental Data
Supplemental Data include Supplemental Discussion, Supplemental
Experimental Procedures, Supplemental References, one table, and
seventeen figures and can be found with this article online at http://
www.cell.com/cgi/content/full/129/5/983/DC1/.
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